Skip to search formSkip to main contentSkip to account menu

daratumumab

Known as: Anti-CD38 Monoclonal Antibody 
A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti… 
National Institutes of Health

Related topics

Related topics

6 relations
5 ML daratumumab 20 MG/ML Injection [Darzalex]Monoclonal AntibodiesNCIt Antineoplastic Agent Terminologyantigen binding

Broader (1)

Antineoplastic Agents

Narrower (1)

Darzalex

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and…
INTRODUCTION. Bortezomib, lenalidomide and dexamethasone (VRd) is considered a standard of care combination therapy for newly… 
2018
2018
Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia—a worthwhile strategy?
Adult ALL is a heterogeneous disease both clinically and genetically. The management of ALL in adults remains a daunting task… 
Review
2017
Review
2017
Novel Therapies in Light Chain Amyloidosis
2017
2017
Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.
8000Background: DARA in combination with established standard of care regimens prolongs PFS, deepens responses, and demonstrates… 
Review
2016
Review
2016
Monoclonal antibodies - A new era in the treatment of multiple myeloma.
2016
2016
Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma.
2015
2015
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
![Graphic][1] Introduction : Daratumumab (DARA) is a human anti-CD38 IgG1κ monoclonal antibody that showed synergistic anti… 
2014
2014
Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
8533 Background: Daratumumab (DARA) (HuMax-CD38), a human IgG1κ monoclonal antibody effectively mediates destruction of CD38… 
2014
2014
Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).
8513 Background: Pts with RR MM received DARA for 9 wks in doses of 0.005-24mg/kg in the GEN501 dose-escalation part (Lokhorst… 
Highly Cited
1996
Highly Cited
1996
Tyrosine Phosphorylation of the c-cbl Proto-oncogene Product Mediated by Cell Surface Antigen CD38 in HL-60 Cells(*)
The human cell surface antigen CD38 is a 46-kDa type II transmembrane glycoprotein with a short N-terminal cytoplasmic domain and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)